Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2007
Business Overview: DaVita is a leading provider of dialysis services and related products. The company operates a network of dialysis centers and provides ancillary services including pharmacy, vascular access, and disease management. A significant portion of revenue is derived from government programs (Medicare/Medicaid) and commercial payors.
Key Financial Metrics
| Metric (in thousands) | Q2 2007 | Q2 2006 | YTD 2007 | YTD 2006 |
|---|---|---|---|---|
| Net Operating Revenues | $1,312,735 | $1,207,816 | $2,590,901 | $2,371,004 |
| Operating Income | $261,217 | $171,752 | $454,534 | $333,827 |
| Net Income | $125,024 | $63,237 | $201,606 | $120,706 |
| Diluted EPS | $1.17 | $0.60 | $1.89 | $1.14 |
| Cash from Operations (YTD) | $213,932 | $232,526 | ||
| Cash & Equivalents (End of Period) | ||||
| Total Debt (Long-term + Current) | $3,707,967 |
Operational Metrics (Q2 2007):
- Total Dialysis Treatments: 3,792,419
- Average Revenue per Treatment: $338
- Patient Care Costs as % of Revenue: 67.9%
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 8.7% year-over-year (Q2 2007 vs. Q2 2006) and 9.0% for the six-month period. Growth was driven by a 5.0% increase in treatment volume and a 3.0% increase in revenue per treatment.
- Profitability Surge: Net income for Q2 2007 nearly doubled compared to Q2 2006 ($125M vs. $63M). This was significantly aided by a one-time valuation gain of $55.3 million recorded in June 2007 related to the termination of purchase obligations for dialysis machines under the Alliance and Product Supply Agreement with Gambro due to an FDA import ban.
- Expense Trends: Patient care costs decreased as a percentage of revenue (67.9% in Q2 2007 vs. 69.8% in Q2 2006), primarily due to lower intensity of physician-prescribed pharmaceuticals. General and administrative expenses increased due to higher labor costs, legal/compliance fees, and stock-based compensation.
- Debt Reduction: The company issued $400 million in senior notes in February 2007 and used the proceeds to pay down Term Loan B. The overall effective interest rate on debt decreased to 6.43% as of June 30, 2007.
Guidance, Outlook, and Risks
Guidance and Outlook
- 2007 Operating Income: Revised upward to a range of $790 million to $820 million (previously $740-$780 million).
- 2008 Operating Income: Projected at $790 million to $850 million, excluding potential impacts of Medicare legislation. Management noted "unusual earnings uncertainty" for 2008.
- Capital Expenditures: Expected to spend $110-$120 million on maintenance/IT and $200-$220 million on new center development and acquisitions in 2007.
- Operating Cash Flow: Anticipated to generate $480 million to $530 million in 2007.
Risks and Contingencies
- Government Investigations: The company is subject to ongoing civil and criminal investigations by the U.S. Attorney's Offices in the Eastern District of Missouri and New York, as well as the Office of Inspector General (Houston). These inquiries focus on EPO utilization, billing practices, and relationships with physicians. Negative findings could result in substantial penalties or exclusion from Medicare/Medicaid.
- Regulatory Changes: Significant risk regarding changes to Medicare ESRD payment structures, specifically the potential bundling of pharmaceuticals (like EPO) into the composite rate, which could reduce revenues. FDA labeling changes for EPO have already led to decreased utilization.
- Commercial Payor Rates: Approximately 35% of revenue comes from commercial payors. Consolidation among payors and downward pressure on rates pose a material risk to profitability.
- Integration Risks: Ongoing integration of DVA Renal Healthcare billing and clinical systems carries risks of collection delays and compliance issues.
Investor Verification Checklist
- Valuation Gain Sustainability: Verify the impact of the $55.3 million one-time gain on the valuation of the Gambro supply agreement and confirm it is not a recurring revenue stream.
- EPO Utilization Trends: Monitor the trajectory of EPO and Aranesp utilization rates and the resulting impact on revenue per treatment, given the FDA black box warnings and CMS policy proposals.
- Legal Exposure: Assess the potential financial impact of the ongoing U.S. Attorney investigations and the likelihood of penalties or exclusion from government programs.
- Debt Covenants: Confirm the company's leverage ratio remains below the 3.5:1 threshold to maintain flexibility on capital expenditures and share repurchases.
- Commercial Rate Negotiations: Review the status of contract renewals with commercial payors to gauge the risk of rate reductions in the coming quarters.